Literature DB >> 35761407

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.

Yali Yi1,2, Jing Cai1,2, Peng Xu1,2, Le Xiong1,2, Zhiqin Lu1,2, Zhimin Zeng3,4, Anwen Liu5,6.   

Abstract

Entities:  

Year:  2022        PMID： 35761407      PMCID： PMC9238048          DOI： 10.1186/s12967-022-03453-0

Source DB:  PubMed          Journal:  J Transl Med        ISSN： 1479-5876            Impact factor:   8.440


× No keyword cloud information.
  1 in total

1.  Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.

Authors:  Yali Yi; Jing Cai; Peng Xu; Le Xiong; Zhiqin Lu; Zhimin Zeng; Anwen Liu
Journal:  J Transl Med       Date:  2022-03-14       Impact factor: 5.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.